Bain Capital Life Sciences Investors, LLC Nuvalent, Inc. Transaction History
Bain Capital Life Sciences Investors, LLC
- $489 Million
- Q2 2024
A detailed history of Bain Capital Life Sciences Investors, LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Bain Capital Life Sciences Investors, LLC holds 2,697,267 shares of NUVL stock, worth $267 Million. This represents 41.86% of its overall portfolio holdings.
Number of Shares
2,697,267
Previous 2,697,267
-0.0%
Holding current value
$267 Million
Previous $203 Million
1.03%
% of portfolio
41.86%
Previous 30.59%
Shares
3 transactions
Others Institutions Holding NUVL
# of Institutions
178Shares Held
56.6MCall Options Held
527KPut Options Held
131K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.98 Billion31.83% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.57MShares$453 Million14.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.78MShares$374 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$300 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.55MShares$253 Million5.59% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $4.26B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...